Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous intravenous labetalol for blood pressure control in neurosurgery
TCTR20221227005Completed
- Sponsor
- N/A
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of labetalol in hypertension (HTN), sponsored by N/A. Primary endpoints: Safety of continuous intravenous labetalol and Efficacy of blood pressure control. Started Dec 2022; status: completed.
02
Drugs
labetalol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on TCTR20221227005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221227005.